OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 30th ...

Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety profile and durable structural and functional benefits in ...

Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.Laru-zova was ge ...

Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular ...

Powerful storms that spawned at least three tornadoes tore through several Mississippi counties, damaging around 500 homes, uprooting trees and injuring at least 17 ...

On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue ...

A new clinical classification scheme is presented, entitled “Acute Pulmonary Embolism Clinical Categories,” with 5 categories (A-E) and subcategories, ranging from low to high risk for adverse ...

Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsTamara Thornton - Director of Finance, Treasury ...

A new kind of CRISPR that destroys cells rather than gene editing them has shown potential for killing sick cells while leaving healthy cells untouched. The technology has largely been tested in cells ...

The firm made the announcements as part of its Q1 financial report, in which it posted $2.99 billion in revenue, up 8 percent ...

Stuart Orkin and Swee Lay Thein shared a Breakthrough Prize in Life Sciences for their research on genetic causes of sickle ...

As Q1 earnings arrive, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least ...